Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of Actn3 genotype on dexamethasone response in skeletal muscle

ABSTRACT: To examine the effect of alpha-actinin-3 deficiency on muscle atrophy response following dexamethasone treatment.

ORGANISM(S): Mus musculus

PROVIDER: GSE169571 | GEO | 2021/03/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

ACTN3 genotype influences androgen response in skeletal muscle

Project description:Androgens act through androgen receptor (AR) to maintain muscle mass. Evidence suggests that this pathway is influenced by ACTN3 (α-actinin-3) - “the Gene for Speed”. Given that one in 5 people worldwide lack α-actinin-3, it is possible they may respond to androgens differently. In this study, we show that α-actinin-3 deficiency decreases AR in skeletal muscles of mice and humans (in males and females), and that AR levels positively correlate with α-actinin-3 expression in a dosage dependent manner. α-Actinin-3 deficiency exacerbates gastrocnemius muscle mass loss with androgen deprivation in male mice, and stunts the muscle growth response to dihydrotestosterone at the onset of puberty in female mice. This is mediated by differential activation of pathways regulating amino acid metabolism, intracellular transport, autophagy, mitochondrial activity, MAPK and calcineurin signalling, which may be driven by 7 key genes that are both androgen sensitive and α-actinin-3-dependent in expression. Our results highlight a role for α-actinin-3 in the regulation of muscle mass and suggest that ACTN3 is a genetic modifier of androgen action in skeletal muscle.

2025-08-01 | GSE299080 | GEO

Induction of muscle atrophy by tumor and dexamethasone regulates a distinct set of proteins from atrophy caused by aging

Project description:To assess changes in the muscle proteome that due to tumor burden and dexamethasone treatments and compare proteomic changes that occur in atrophy due to tumor burden and dexamethasone treatment with atrophy caused by aging. Regulators of muscle atrophy induced by diseases such as cancer or drugs such as dexamethasone are largely unknown. We would therefore like to determine the proteomic signature of atrophying muscle caused by tumor burden (LLC cell injected mice) and dexamethasone treatment in order to examine possible biomarkers and regulators of muscle atrophy. We would also like to compared the proteomic signature of different modes of muscle atrophy to determine similarities and differences in the possible biomarkers and regulators.

2022-02-22 | PXD027490 | Pride

Effect of Actn3 genotype on dexamethasone response in skeletal muscle

Project description:Effect of Actn3 genotype on dexamethasone response in skeletal muscle

| PRJNA717028 | ENA

Jakyak-gamcho-tang ameliorates dexamethasone-induced muscle atrophy and muscle dysfunction

Project description:Jakyak-gamcho-tang ameliorates dexamethasone-induced muscle atrophy and muscle dysfunction

| PRJNA945385 | ENA

Jakyak-gamcho-tang ameliorates dexamethasone (DEX)-induced muscle atrophy and muscle dysfunction [Gastrocnemius and Soleus]

Project description:Jakyak-gamcho-tang (JGT) is a herbal medicine that has been traditionally prescrived for pain control including muscular pain. Muscle atrophy is a disease that is characterized with a gradual muscle loss. Muscle atrophy is clearly observed in experimental animals that receive a repeated high-dose of an artificial glucocorticoid, dexamethasone (DEX). This transcriptome analysis aims to investigate the changes in global gene expression profiles in gastrocnemius (GA) and soleus (SO) muscle tissues from mice with DEX-induced muscle atrophy in the presence or absence of JGT co-treatment.

2023-03-21 | GSE227495 | GEO

Genome-wide analysis of dexamethasone-responsive gene expression in mouse triceps surae muscle

Project description:Analysis of dexamethasone-regulation of muscle mass at gene expression level. The hypothesis tested in the present study was that the presence of MuRF1 contributes to the extent of gene expression changes observed in specific sets of genes during a challenge leading to muscle atrophy. Results provide important information on the response of triceps surae muscle to synthetic glucocorticoid treatment, such as specific cell signaling and metabolic enzyme genes, that may be influenced by MuRF1 during atrophy. Total RNA obtained from isolated triceps surae muscle subjected to 3 or 14 days dexamethasone treatment compated to untreated littermate control muscles.

2013-02-12 | E-GEOD-44208 | biostudies-arrayexpress

Transcriptome profiling of THSG treatment in a dexamethasone-induced muscle atrophy model using C2C12 myotubes

Project description:This study investigates the effects of 2,3,5,4′-Tetrahydroxystilbene-2-O-β-D-glucoside (THSG) on gene expression changes in C2C12 myotubes under dexamethasone-induced muscle atrophy conditions. Using RNA-seq, we identified transcriptomic alterations associated with THSG treatment, aiming to elucidate its potential protective role against muscle atrophy.

2025-04-09 | GSE293772 | GEO

GW8510 alleviated muscle atrophy and skeletal muscle dysfunction in mice through AMPK/PGC1α signaling

Project description:Preventing and restoring muscle loss and function is essential for elderly individuals. In this study, we expect to investigate the protective effect of GW8510 on muscle atrophy. We established mouse models of muscle atrophy induced by denervation, dexamethasone, and glycerol. We assessed the muscle weight-to-body weight ratio, the cross-sectional area of various muscles, grip strength, fatigue tasks, and serum analysis. In vitro, we created dexamethasone-induced C2C12 myotube atrophy and evaluated mitochondrial function. Additionally, we utilized real-time polymerase chain reaction, immunoblotting, and siRNA transfection to explore the potential molecular mechanisms following treatment with GW8510. Results showed that Treatment with GW8510 resulted in a significant increase in the gastrocnemius and soleus muscle ratios in denervation mice (7% and 3%, respectively, P < 0.001), alongside an increase in cross-sectional area. Moreover, GW8510 notably improved grip strength and superoxide dismutase (SOD) activity (P < 0.0001), with similar protective effects observed in dexamethasone and glycerol-induced muscle atrophy and injury models. Furthermore, GW8510 reduced reactive oxygen species production (P < 0.01), increased mitochondrial DNA copy number (P < 0.01), maintained mitochondrial dynamics, and enhanced antioxidant activity in C2C12 myotubes. Mechanistically, GW8510 significantly inhibited the expression of atrophy-related markers Fbxo32 and Trim63 (P < 0.01) while activating AMPK (P < 0.01). The knockdown of small interfering RNA targeting Pgc1α negated the effects of GW8510. Overall, GW8510 mitigated muscle atrophy through the activation of the AMPK/ PGC1α pathway. Our findings suggest that GW8510 could serve as a novel therapeutic agent for the prevention of muscle atrophy.

2025-07-16 | GSE298338 | GEO

Jakyak-gamcho-tang ameliorates dexamethasone-induced muscle atrophy and muscle dysfunction [C2C12]

Project description:Jakyak-gamcho-tang ameliorates dexamethasone-induced muscle atrophy and muscle dysfunction [C2C12]

| PRJNA945399 | ENA

Genome-wide analysis of dexamethasone-responsive gene expression in mouse triceps surae muscle

2013-02-12 | GSE44208 | GEO